Day: August 27, 2025

MANITOWOC, Wisc., Aug. 27, 2025 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today announced that it will participate in Singular Research’s Emerging Growth & Value Alpha Leaders Conference. The conference takes place September 10, 2025, at the AMA Executive Conference Center at 1601 Broadway (entrance on 48th Street) in New York City. Orion Chief Executive Officer Sally Washlow will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The Orion presentation is scheduled for September 10, 2025, at 9:45 a.m. EDT. To view the presentation, please visit Singular Research Emerging Growth and Value Alpha Leaders Conference at...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 27, 2025 (GLOBE NEWSWIRE) — Critical One Energy Inc. (formerly Madison Metals Inc.) (“Critical One” or the “Company”) (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that, further to the press release issued on August 18, 2025, the Company has closed its oversubscribed, non-brokered financing and issued 5,001,999 units (the “Units”) at a price of CDN$0.60 per Unit for aggregate gross proceeds of CDN$3,001,199.40 (the “Private Placement”). Each Unit consists of one (1) common share in the capital of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each full Warrant entitles the holder thereof to purchase one Common Share for a price of CDN$1.00 for a period of eighteen (18) months from...

Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming monthsCOPENHAGEN, Denmark, August 27, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting data and company updates at numerous scientific and investor conferences throughout the second half of 2025. Further to presenting, Evaxion will engage with stakeholders, including potential partners, at the conferences. With events taking place in both the US, Europa and Asia, we will have many opportunities to liaise with global audiences as part of our strategy to identify potential partners and opportunities for both business partnerships and scientific collaborations. “As a scientific and innovative...

TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) — Slide Insurance Holdings, Inc. (“Slide” or the “Company”) (Nasdaq: SLDE) today announced that its Board of Directors has authorized the repurchase of up to $75 million of the Company’s common stock. The authorization is effective immediately, has no time limit, and may be modified, suspended or discontinued at any time. “The initiation of our stock repurchase program is reflective of our strong confidence in our strategic direction, superior underwriting capabilities and well-capitalized balance sheet,” said Bruce Lucas, Chairman and Chief Executive Officer of Slide. “Slide has a very robust balance sheet from our recent IPO as well as better than expected net margins. As a result, our capital position is very strong and we will use it to repurchase common stock when we believe it is...

BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY At-Home trial suggesting a significantly larger potential market opportunity Company to host conference call at 8 a.m. EDT today NEW HAVEN, Conn., Aug. 27,...

WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September.On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Cantor Global Healthcare Conference in New York, NY.On Tuesday September 9, 2025, at 9:00 AM EDT, Dr. Walker will provide a corporate presentation during the H.C. Wainwright 27th Annual Global Investment Conference in New York, NY.Live and archived webcasts of both events will be accessible on the Events page of https://www.aclaristx.com/....

ATHENS, Greece, Aug. 27, 2025 (GLOBE NEWSWIRE) — C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing seaborne transportation services, announced today that it will release its second quarter financial results for the period ended June 30, 2025 before the market opens in New York on September 2, 2025. On September 2, 2025 at 10:00 am ET, the company’s management will host a conference call to present the results and the company’s operations and outlook. Slides and audio webcast: There will also be a live and then archived webcast of the conference call, through the C3is Inc. website (www.c3is.pro). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. Please note that this will be a listen-only mode presentation. ABOUT C3is Inc. C3is Inc....

New Peer-Reviewed Publication Highlights Landmark Meeting Co-Sponsored by LIXTE DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, highlights the publication of a new manuscript in Trends in Cancer (July 2025, Vol. 11, No. 7, https://doi.org/10.1016/j.trecan.2025.04.009) describing the first international conference on activation of oncogenic signaling as a cancer treatment strategy. The landmark meeting was co-sponsored by LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) and co-organized by Professor Rene Bernards, and board member of LIXTE. At the conference, compelling new data was presented showing that LIXTE’s lead compound LB-100 can mediate activation of oncogenic signaling, a process that proves toxic...